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Biotinidase Deficiency: A Reversible Neurometabolic Disorder
 (An Iranian Pediatric Case Series)
Abstract
Objective
Biotinidase deficiency is one of the rare congenital metabolic disorders with 
autosomal recessive inheritance. If this disorder is diagnosed in newborn 
period, could be prevented well from mental and physical developmental 
delay and most of clinical manifestations. 
Materials & Methods
The patients were diagnosed as biotinidase deficiency in Neurology 
Department of Mofid Children’s Hospital in Tehran, Iran, between 2009 and 
2012 were included in this study. This study was conducted to define the 
age, gender, past medical history, developmental status, general appearance, 
clinical manifestations, neuroimaging findings, and response to treatment in 
16 patients with biotinidase deficiency in this department.
Results
In clinical presentation, cutaneous lesions were not found in 37% of the 
patients and 43% patients had not alopecia. 75% patients had abnormal 
neuroimaging that in 56% of them, generalized brain atrophy and myelination 
delay were found. Results of the present study showed the efficacy of biotin in 
early diagnosed patients with seizure and dermatological manifestations. The 
seizure and skin manifestations were improved after biotin therapy.
Conclusion
According to the results of this study, we suggest that early assessment and 
diagnosis have an important role in the prevention of disease progression and 
clinical signs.
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Introduction
Biotin is a very important vitamin that found in some foods. It plays an important 
role as cofactor for pyruvate, propionyl-CoA, beta-methylcrotonyl-CoA and 
two isoenzymes of acetyl-CoA carboxylasein-gluconeogenesis, amino acid 
catabolism, and fatty acid synthesis (1).
Biotinidase deficiency is a rare and treatable inherited neurometabolic disorder (2) 
with an estimated incidence of 1:61, 067 population. This disorder in its severe 
form is much rarer with incidence of 1:137401 (3). Clinical findings of this disorder 
include neurological (seizure, ataxia, hypotonia, neurodevelopmental delay), 
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(37.5%). In past medical history, one patient had a 
history of recurrent vomiting and another one had 
anorexia; two other patients had a history of recurrent 
respiratory and urinary infections; one of the patients 
had a history of loss of consciousness attacks; one had 
bilateral undescended testicles; and two cases had a 
history of  severe restlessness. In physical examination, 
10 patients had cutaneous involvement; 3 had 
erythematous lesions in pre-orifices (oral and anal), one 
had cradle cap (Seborrheic dermatitis) lesions, and one 
had erythematous, maculopapular and crusted lesions. 8 
patients had alopecia and one of them had blond hair. 
Weights of 3 patients were less than 5% percentile 
and 3 other patients had microcephaly (less than 5% 
percentile). Five patients had motor vision disorders (3 
with strabismus and 2 with nystagmus). Hypertonicity 
was found in 8 patients.
Three patients had abnormal visual evoked potential 
(VEP) and 4 patients had abnormality in their auditory 
brainstem response (ABR). In lab data, 8 patients had 
increased levels of ammonia and lactate. Three cases 
had high AST and ALT. CBC, VBG (except one patient 
with acidosis), serum levels of calcium, phosphorus, 
triglyceride, and cholesterol were normal. Abdominal 
sonography showed hepatomegaly in one patient. 
Electroencephalography (EEG) in 6 patients was 
abnormal and had not special pattern. In neuroimaging 
data, 12 patients had abnormal neuroimaging that in 9 
patients, generalized brain atrophy and myelination delay 
were found in brain imaging, CT scan showed multiple 
calcification in 1 case. One patient had left hemiatrophy, 
two showed dismyelination in white matter, and one had 
abnormal signal changes in basal ganglia.
All of the cutaneous and hair symptoms were cured with 
biotin therapy after 3 to 6 months. Seizure in all patients 
was stopped (except one patient that in this patient, 
seizure was decreased).
In 3 patients with vision and hearing disorders, their 
symptoms decreased (Table1).
Discussion 
The results of this study demonstrated that biotin 
therapy in patients with biotinidase deficiency 
can reduce, prevent or improve neurological, 
dermatological and other manifestations of biotinidase 
dermatological (eczematous skin rash, seborrheic 
dermatitis),  immunological, ophthalmological, 
respiratory problems (hyperventilation, apnea and 
laryngeal stridor), and alopecia (1,4).
Laboratory findings include abnormal organic acids in 
the urine, metabolic acidosis and elevated lactate and 
pyruvate levels in blood. Diagnosis can be confirmed 
by measuring blood biotinidase activity (5,6). 
Neuroradiological findings include encephalopathy 
and cerebral atrophy, cerebral edema and bilateral 
compensatory ventriculomegaly (4). Neurological, 
cutaneous and neuroimaging finding scan improve or 
become normal after biotin treatment in biotinidase 
deficiency (4,7). Some of these symptoms can be 
cured but some of  the mremain such as hearing loss, 
ophthalmic defects and mental retardation (8,9).
Materials &Methods
Patients were diagnosed as biotinidase deficient 
according to clinical manifestations, developmental 
milestones, dermatological symptoms, seizures and 
neuroimaging findings.  Diagnosis was confirmed 
in all the patients based on assessment of biotinidase 
activity at metabolic disorders reference laboratory in 
Germany. The results of biotin therapy were assessed 
in all the patients. The mean dosage of biotin was 5-20 
mg/day. 
patient’s data were evaluated and categorized as age, 
gender, development status, general appearance, 
clinical manifestations, and neuroimaging findings. 
The data of this observational study were analyzed 
using descriptive method and no statistical testing was 
applied.
Results
Sixteen patients were included in this study. They were 
7 males and 9 females and the age range was from 1.5 
months to 52 months. all patients were offspring of 
consanguineous marriage, so that in 13 patients, their 
parents were first cousin and in 3 other patients, their 
parents were second cousin. Five patients had a history of 
neonatal hospitalization because of respiratory distress, 
icter, seizure, or irritability.
13 patients had a history of seizure that most common 
form of seizures was tonic and myoclonic seizures 
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patients were the offspring of consanguineous marriage. 
Cutaneous lesions were not found in 37% of patients 
and 43% patients did not have alopecia or any other 
symptoms in their hair, so absence of these symptoms 
do not reject the existence of biotinidase deficiency. 
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deficiency. Dermatological manifestations included 
alopecia, loss of hair color, hypopigmentation, and 
eczematous and erythematous perioral and perianal 
papules. These findings are secondary to abnormal 
fatty acid synthesis because of carboxylase deficiency. 
Dermatological manifestations responded to 
administration of biotin 3 to 6 months after initiation 
of the treatment. The most frequent seizure types in 
patients with biotinidase deficiency were tonic and 
myoclonic. Generalized tonic seizures were seen in 
three patients and myoclonic seizures were seen in 
three cases and all of them were resolved with biotin 
therapy. It is important that seizures did not respond 
to conventional therapies, but had rapid improvement 
in response to biotin therapy. Cutaneous symptoms 
and neurodevelopmental delay were also improved 
after treatment with biotin.
These findings are similar to the results of studies by 
Wolf and Grunewald et al. that reported biotin therapy in 
biotinidase deficient infants with seizures (untreatable 
form of seizures with antiepileptic drugs), cutaneous 
manifestation, visual and auditory abnormalities, 
neuroradiological findings such as encephalopathy, 
and lab data such as elevated blood lactate and 
pyruvate concentrations is important to reduce these 
manifestations (1,10). If biotinidase deficient patients 
do not treated by biotin at early stages or infancy, 
irreversible neurological damage, dermatological 
manifestations and other symptoms will progress (11).
Symptoms of biotinidase deficiency in this study are 
similar to previous study that contained cutaneous 
lesions, alopecia, neurodevelopmental delay, and 
brain atrophy, but in our study, there were special 
notices, such as all patients were the offspring of 
consanguineous marriage. Cutaneous lesions were not 
found in 6 patients and 7 patients did not have alopecia 
and symptoms in their hair.
MRI in half of the patients was abnormal. Cutaneous 
symptoms were cured with biotin therapy, and 
neurological symptoms such as seizure, vision and 
hearing impairments improved. 
In conclusion, this study demonstrated that using 
biotin as an early treatment in biotinidase deficiency 
has a therapeutic effect in patients with this reversible 
neurometabolic disorder. Our study showed that all 
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Fig 1. 4 month -Boy- case of biothinidase deficiency pre 
treatment
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